21 November 2016

Embryyo Technologies Private Limited


Low birth weight is a serious public health concern globally and is associated with both short term and long term consequences. Babies undernourished in the womb are at a higher risk of dying during their early months and years. Those who survive have impaired immune function and an elevated risk of non-communicable and cardiovascular diseases, reduced muscular strength and cognitive disabilities.

Embryyo commits to building a novel and sensitive tool for predicting intra-uterine growth retardation during antenatal care in the community. The tool for fetal growth monitoring will not depend on expensive imaging modalities, such as an ultrasound, and it will be possible for front-line health workers to understand and use. Such a cost effective screening tool for intra-uterine growth retardation will help the health system in identifying high risk pregnancies and addressing them with better nutritional and clinical monitoring strategies. This commitment, equivalent to $60,000, is focused on developing the innovation, valued at $2,000 – 2,500 per unit, and establishing its clinical efficacy by September 2016, for possible inclusions in intervention packages during antenatal care by March 2017.